Selected article for: "acute infection and additional cost"
Author: Dabholkar, Neha; Gorantla, Srividya; Dubey, Sunil Kumar; Alexander, Amit; Taliyan, Rajeev; Singhvi, Gautam
Title: Repurposing methylene blue in the management of COVID-19: Mechanistic aspects and clinical investigations
  • Cord-id: joimj68u
  • Document date: 2021_8_10
    • ID: joimj68u
    Snippet: The severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is the most recent coronaviruses, which has infected humans, and caused the disease COVID-19. The World Health Organization has declared COVID-19 as a pandemic in March 2020. The SARS-CoV-2 enters human hosts majorly via the respiratory tract, affecting the lungs first. In few critical cases, the infection progresses to failure of the respiratory system known as acute respiratory distress syndrome acute respiratory distress syndrom
    Document: The severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is the most recent coronaviruses, which has infected humans, and caused the disease COVID-19. The World Health Organization has declared COVID-19 as a pandemic in March 2020. The SARS-CoV-2 enters human hosts majorly via the respiratory tract, affecting the lungs first. In few critical cases, the infection progresses to failure of the respiratory system known as acute respiratory distress syndrome acute respiratory distress syndrome may be further associated with multi-organ failure and vasoplegic shock. Currently, the treatment of COVID-19 involves use of antiviral and anti-cytokine drugs. However, both the drugs have low efficacy because they cannot inhibit the production of free radicals and cytokines at the same time. Recently, some researchers have reported the use of methylene blue (MB) in COVID-19 management. MB has been used since a long time as a therapeutic agent, and has been approved by the US FDA for the treatment of other diseases. The additional advantage of MB is its low cost. MB is a safe drug when used in the dose of < 2 mg/kg. In this review, the applicability of MB in COVID-19 and its mechanistic aspects have been explored and compiled. The clinical studies have been explained in great detail. Thus, the potential of MB in the management of COVID-19 has been examined.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and acute myocarditis: 1, 2, 3, 4, 5, 6, 7, 8
    • abdominal pain and administration route: 1
    • abdominal pain and long history: 1, 2
    • abdominal pain and low efficacy: 1
    • abdominal pain and lung infection: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and adenine dinucleotide phosphate: 1
    • acute ards respiratory distress syndrome and administration route: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and low efficacy: 1, 2
    • acute ards respiratory distress syndrome and lung infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute myocarditis and administration route: 1
    • administration route and liver bone marrow: 1
    • administration route and long history: 1, 2
    • administration route and low efficacy: 1, 2, 3
    • administration route and lung infection: 1, 2, 3
    • liver bone marrow and lung infection: 1, 2
    • local lung infection and lung infection: 1, 2, 3, 4
    • long history and low efficacy: 1
    • long history and lung infection: 1, 2
    • low efficacy and lung infection: 1